The data the study are based upon are potentially patient identifiable. As such, they are not publically available. They may be accessed, however, if researchers acquire Section 251 approval and appropriate ethical approvals from the National Cancer Intelligence Network <http://www.ncin.org.uk/collecting_and_using_data/data_access>.

INTRODUCTION {#sec005}
============

Colorectal cancer (CRC) is a common disease in the UK affecting around 40,000 individuals annually and accounting for 16,000 cancer related deaths each year \[[@pone.0117816.ref001]\]. Despite major advances in the medical management of CRC over the last 25 years, five-year survival remains at only around 55% \[[@pone.0117816.ref001]\].

A principle metric of patient prognosis of CRC is stage at presentation \[[@pone.0117816.ref002]\] however there is significant variability in overall survival (OS) of patients with apparently same stage disease and understanding these differences is clinically important.

There is evidence of familial concordance for survival in a number of cancers, including CRC \[[@pone.0117816.ref003]\], which suggests that inherited genetic variation can contribute to CRC prognosis. Additionally, studies have reported associations with survival from CRC with genetic variants alone or in combination with specific types of chemotherapy \[[@pone.0117816.ref004]--[@pone.0117816.ref006]\]. Hence, as a potential prognostic factor the concept of germline variation imparting inter-individual variability in tumour development, progression and metastasis is receiving increased attention \[[@pone.0117816.ref007]--[@pone.0117816.ref011]\].

Genome-wide association studies (GWAS) have been successful in identifying single nucleotide polymorphisms (SNPs) that are significantly associated with an individual's risk of developing a CRC \[[@pone.0117816.ref012],[@pone.0117816.ref013]\]. In European populations GWAS located CRC susceptibility SNPs have been identified at 1q41, 3q26.2, 5p15.33, 6p21, 8q23.3, 8q24.21, 10p14, 11q13.4, 11q23.11, 12q13.3, 14q22.2, 15q13.3, 16q22.1, 18q21.1, 19q13, 20p12.3, 20q13.33, and Xp22.2 \[[@pone.0117816.ref012]--[@pone.0117816.ref016]\]. As well as influencing CRC risk, it is entirely plausible these variants may also impact on patient outcome following the diagnosis of CRC.

This hypothesis has been variously examined by a number of researchers but with contradictory results \[[@pone.0117816.ref017]--[@pone.0117816.ref024]\]. Disparity may be due to the relatively small and heterogeneous cohorts of individuals analysed which had limited power to detect clinically important relationships between SNP genotype and outcome and, hence, the prognostic significance of these CRC susceptibility variants remains controversial. To address shortcomings in previous studies we have made use of the recent linkage \[[@pone.0117816.ref010]\] of the large National Study of Colorectal Cancer Genetics (NSCCG) \[[@pone.0117816.ref025]\] with the data in the National Cancer Data Repository (NCDR) \[[@pone.0117816.ref026]\]. This linkage has offered an opportunity to relate genotype and outcome across a larger population than has previously been possible. Using these data, this study aimed to investigate whether 19 CRC susceptibility SNPs also exerted an influence of survival from the disease.

MATERIALS AND METHODS {#sec006}
=====================

Patients and record linkage {#sec007}
---------------------------

Full details of the NSCCG have been published elsewhere \[[@pone.0117816.ref025]\] but, in brief, the study collected DNA and clinicopathological data from over 20,000 individuals with colorectal cancer and a series of spouse/partner controls with the aim of creating a unique resource for the identifying low-penetrance CRC susceptibility genes. All individuals within this study for whom SNP information were available and who could be linked to the NCDR were, therefore, identified and matched using the method described previously \[[@pone.0117816.ref010]\]. To minimise bias, cases were excluded from the analysis if there was more than a year between the diagnosis of CRC in an individual recorded in the NCDR and their recruitment to the NSCCG ([Fig. 1](#pone.0117816.g001){ref-type="fig"}).

![Matching of the NSSCG study cohort and the NCDR.](pone.0117816.g001){#pone.0117816.g001}

All clinical information and biological samples were obtained after fully informed consent was obtained from participating individuals, and in accordance with the tenets of the Declaration of Helsinki. Ethical approval for the both the NSCCG and its linkage to the NCDR were obtained from Multi-Centre Research Ethics Committees (MREC/98/2/67; MREC02/0/97; REC08/S0501/66)

Genotyping {#sec008}
----------

DNA was extracted from EDTA acid-venous blood samples by conventional methodologies and PicoGreen quantified (Invitrogen Corporation, Carlsbad, California; now Life Technologies). Nineteen SNPs were selected that had been reported to be associated with CRC from 14 chromosomal regions---rs6691170 (1q41), rs10936599 (3q26.2), rs1321311 (6p21), rs16892766 (8q23.3), rs6983267 (8q24.21) rs10795668 (10p14), rs3824999 (11q13), rs3802842 (11q23.1), rs11169552 (12q13.13), rs1957637 (14q22), rs4444235 (14q22.2), rs4779584, (15q13.3), rs9929218 (16q22.1), rs4939827 (18q21.1), rs10411210 (19q13.11), rs4813802 (20p12), rs961253 (20p12.3) rs4925386 (20q13.33) and rs5934682 (xp22). SNP genotyping was performed by allele-specific polymerase chain reaction (LGC Genomics; <http://www.kbioscience.co.uk>) with primer sequences and conditions available on request. To monitor quality control, we included a set of 136 duplicate samples in assays; genotype concordance was \>99.9%. To confirm genotypes, we sequenced 192 samples chosen randomly from cases and controls; concordance between genotypes was 100%.

Statistical analysis {#sec009}
--------------------

Statistical analyses were conducted using Stata version 13 (State College, Tx, USA). A *P*-value of 0.05 (two sided) was considered to be significant. When commented, a Bonferroni correction for multiple comparisons corresponded to a value of 0.0026 (0.05/19 SNPs). Results are presented without correction for multiple testing to mitigate against type II error. Differences in patient characteristics between groups were assessed using χ^2^ and Kruskal-Wallis tests. The study end-point was five-year overall survival calculated from date of recruitment to the NSCCG to date of death or when censored (30^th^ June 2011). Kaplan-Meier graphs according to genotype were generated and their homogeneity evaluated using log-rank tests. Cox proportional hazards regression analysis was used to estimate hazard ratios (HR) and their 95% confidence intervals (CI) whilst adjusting for age, sex, Dukes' stage of disease at diagnosis, deprivation score, tumour site (colon, rectosigmoid junction or rectum), and year of diagnosis. The *P*-values presented correspond to the significance of a test difference among all three of the genotype groups (common allele homozygote, heterozygote and rare allele homozygote).

The power to demonstrate a relationship between SNP genotype and OS was estimated using sample size formulae for comparative binomial trials. To evaluate the chance of obtaining a false-positive association in our data set and to assess the robustness of previously reported associations between SNP genotype and patient outcome, we made use of the false-positive report probability (FPRP) test \[[@pone.0117816.ref027]\]. The FPRP value is determined by the *P* value, the prior probability for the association, and statistical power. For our analyses, we assumed prior probabilities of 0.05, 0.01 and 0.001; imposing an FPRP cut-off value of 0.5 as advocated \[[@pone.0117816.ref027]\], values less than 0.5 were considered to be noteworthy, being indicative of a robust association.

Meta-analysis of study findings with previously published data was performed using a fixed-effects model, estimating Cochran's Q statistic to test for heterogeneity and the *I* ^*2*^ statistic to quantify the proportion of the total variation between studies.

Ethical approval was obtained for both the NSCCG study (MREC/98/2/67; MREC02/0/97) and the linkage and exploitation of the NSCCG and NCDR data (LR/08/S0501/66).

RESULTS {#sec010}
=======

Linkage {#sec011}
-------

Information on 9,229 individuals recruited to the NSCCG and with SNP information was supplied for linkage to the NCDR. The study population consisted of 4,327 (46.9%) of these individuals who both matched into the NCDR and who were recruited to the NSCCG within a year of the diagnosis of their disease ([Fig. 1](#pone.0117816.g001){ref-type="fig"}).

Descriptive statistics {#sec012}
----------------------

Complete clinical and demographic characteristics of the subjects studied are provided in [Table 1](#pone.0117816.t001){ref-type="table"}. The median age at diagnosis of CRC was 60 years (mean, 58.6 years; standard deviation, 8.0). A total of 2,626 cases (60.7%) had colonic, 416 (9.6%) rectosigmoid and 1,285 (29.7%) rectal tumours; the majority of patients presented with Dukes' stage B and C tumours (3,055, 70.6%).

10.1371/journal.pone.0117816.t001

###### The characteristics of the study population.

![](pone.0117816.t001){#pone.0117816.t001g}

  Characteristic                                             n               \%             
  ---------------------------------------------------------- --------------- -------------- -------------
  Median age at diagnosis (range)                            60              (54--65)       
  Age at diagnosis                                           ≤50             631            14.6
  51--60                                                     1,648           38.1           
  \>60                                                       2,048           2,048          
  Sex                                                        Male            2,570          59.4
  Female                                                     1,757           40.6           
  [Self-reported family history of colorectal cancer]{.ul}   [No]{.ul}       [3,500]{.ul}   [80.9]{.ul}
  [Yes]{.ul}                                                 [827]{.ul}      [19.1]{.ul}    
  Dukes\' stage of disease at diagnosis                      A               252            5.8
  B                                                          1,171           27.1           
  C                                                          1,884           43.5           
  D                                                          596             13.8           
  Unknown                                                    424             9.8            
  Tumour site                                                Colon           2,626          60.7
  Rectosigmoid                                               416             9.6            
  Rectum                                                     1,285           29.7           
  IMD income category                                        Most affluent   1,066          24.6
  2                                                          1,016           23.5           
  3                                                          979             22.6           
  4                                                          739             17.1           
  Most deprived                                              527             12.2           
  Year of recruitment into NSCCG                             2004            789            18.2
  2005                                                       1,489           34.4           
  2006                                                       1,073           24.8           
  2007                                                       813             18.8           
  2008                                                       67              1.6            
  2009                                                       50              1.2            
  2010                                                       46              1.1            
  Year of diagnosis of CRC                                   2003            190            4.4
  2004                                                       1,277           29.5           
  2005                                                       1,292           29.9           
  2006                                                       1,074           24.8           
  2007                                                       366             8.5            
  2008                                                       58              1.3            
  2009                                                       61              1.4            
  2010                                                       9               0.2            

Overall, the 5-year survival rate was 64.3% (95%CI 62.9--65.8%). There were 1,658 (38.3%) deaths across the entire cohort. Survival was strongly associated with tumour stage (P\<0.0001); 5-year survival ranged from 54.9% (95%CI 0.50--0.60) for patients diagnosed with stage D CRC to 88.4% (95%CI 83.6--91.2%) for those with the stage A CRC. Since these survival rates are not significantly different to those documented in previously published studies investigating the prognosis of actively managed CRC patients \[[@pone.0117816.ref028]\], it was concluded that there is no evidence that 'healthy study participant' selection would bias analyses.

Relationship between SNP genotype and OS {#sec013}
----------------------------------------

There was no statistically significant correlation between SNP genotype and the pathological parameters, site and stage. Only one SNP showed evidence of a correlation with OS ([Table 2](#pone.0117816.t002){ref-type="table"}). A significant association were identified between rs4444235 genotype and prognosis, where the hazards ratio for increasing number of variant alleles was 1.13 (95% CI: 1.05--1.22). Hazard ratios for heterozygosity, homozygosity and carrier status were: 1.18 (95% CI: 1.04--1.34) and 1.28 (95% CI: 1.11--1.48), respectively. It should be noted that the association (*P* ~*trend*~ = 0.0015) remained significant if Bonferroni correction for multiple testing was applied (*P* ~*adj*~ = 0.032) and remained noteworthy (i.e. FPRP≤0.5) provided the prior was \>0.001. Kaplan--Meier estimates ([Fig. 2](#pone.0117816.g002){ref-type="fig"}) demonstrated that carriers had lower five-year survival than those with the wild-type genotype (*P*\<0.01).

![Kaplan Meier survival curves for SNP rs4444235.](pone.0117816.g002){#pone.0117816.g002}

10.1371/journal.pone.0117816.t002

###### Unadjusted and risk-adjusted hazard ratios showing the risk of death within five years of diagnosis in relation to SNP status.
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  SNP             Position (nearest gene)   Risk allele   Number of individuals   Number of deaths   Unadjusted   Adjusted                                                 
  --------------- ------------------------- ------------- ----------------------- ------------------ ------------ ---------------- ----------- ---------- ---------------- -----------
  rs10411210      19q13                     C             4,275                   1,632              1.02         0.90--1.16       0.76        1.07       0.94--1.22       0.30
  rs10795668      10p14                     G             4,171                   1,600              1.06         0.98--1.15       0.16        1.04       0.96--1.13       0.34
  rs10936599      3q26                      C             4,285                   1,640              1.05         0.96--1.14       0.26        1.07       0.99--1.17       0.10
  rs11169552      12q13                     C             4,257                   1,632              1.01         0.93--1.10       0.75        1.04       0.96--1.14       0.33
  rs1321311       6p21                      C             4,254                   1,626              1.00         0.92--1.08       0.94        0.98       0.90--1.07       0.62
  rs16892766      8q23                      C             4,270                   1,633              0.93         0.82--1.05       0.23        0.94       0.83--1.06       0.32
  rs1957637       14q22                     A             4,303                   1,647              1.00         0.93--1.07       0.98        0.97       0.90--1.04       0.34
  rs3802842       11q23                     C             4,244                   1,625              0.97         0.90--1.05       0.48        0.97       0.90--1.05       0.50
  rs3824999       11q13                     A             4,263                   1,634              0.99         0.92--1.06       0.77        1.02       0.95--1.10       0.58
  **rs4444235**   **14q22**                 **C**         **4,278**               **1,638**          **1.12**     **1.04--1.50**   **0.001**   **1.13**   **1.05--1.22**   **0.001**
  rs4779584       15q13                     T             4,251                   1,624              1.02         0.94--1.11       0.69        1.01       0.93--1.10       0.85
  rs4813802       20p12                     G             4,223                   1,615              0.98         0.91--1.06       0.59        0.98       0.91--1.06       0.64
  rs4925386       20q13                     C             4,263                   1,630              1.06         0.97--1. 14      0.19        1.09       1.01--1.18       0.03
  rs4939827       18q21                     T             4,268                   1,630              0.97         0.91--1.05       0.47        0.94       0.87--1.01       0.08
  rs5934683       Xp22                      C             4,225                   1,608              0.98         0.92--1.04       0.51        0.96       0.90--1.02       0.14
  rs6691170       1q41                      T             4,266                   1,632              1.01         0.94--1.09       0.75        1.05       0.97--1.13       0.22
  rs6983267       8q24                      G             4,246                   1,623              1.07         0.99--1.12       0.08        1.05       0.98--1.13       0.16
  rs961253        20p12                     A             4,249                   1,624              0.92         0.86--1.00       0.05        0.97       0.90--1.04       0.40
  rs9929218       16q22                     G             4,271                   1,634              1.01         0.94--1.10       0.73        1.01       0.93--1.10       0.76

Commentary on previously published studies {#sec014}
------------------------------------------

A number of previous studies have evaluated the relationship of rs4444235 and other risk SNPs with patient prognosis ([Table 3](#pone.0117816.t003){ref-type="table"}). Tenesa *et a l* \[[@pone.0117816.ref021]\] analysed 10 CRC susceptibility variants but found no association with OS or CRC-specific survival (CSS). Xing *et al* \[[@pone.0117816.ref022]\] analysed six SNPs in a small cohort of patients in relation to recurrence and death and generated evidence suggesting that rs10795668 (10p14) might influence recurrence (*P* = 0.007, *P* ~*adj*~ = 0.042). The effect observed was strongest in those receiving chemotherapy. Phipps *et al* \[[@pone.0117816.ref020]\] studied 16 CRC SNPs (including some also analysed by Tenesa *et al* \[[@pone.0117816.ref021]\] and survival in 2,611 CRC patients ascertained from five cohort studies. They reported the 18q21 variant rs4939827 affected OS (*P* = 0.002; *P* ~*adj*~ = 0.03). Most recently Abuli and co-workers \[[@pone.0117816.ref017]\] reported on the relationship between 16 CRC risk SNPs CRC patients requited to the Spanish EPICOLON consortium. Genetic variants rs9929218 at 16q22.1 and rs10795668 at 10p14 were reported to have an effect on OS (*P* = 0.0179 and 0.057, respectively) albeit neither robust after adjustment for multiple testing (*P* ~*adj*~ = 0.28 and 0.91, respectively). Most recently, Hoskins *et al* \[[@pone.0117816.ref019]\] have reported on the relationship between 11 SNPs and survival. The only associations reported to be significant was for homozgosity for 8q24 SNPs rs7013278, rs7014346 (*P* = 0.01 and 0.03 respectively, *P* ~*adj*~ for number of risk loci = 0.06 and 0.18 respectively). Contemporaneously Dai and co-workers \[[@pone.0117816.ref018]\] reported on the relationship between 26 SNPs in 10 of the GWAS risk loci in a cohort restricted to individuals with Dukes' stage B and C cancers. rs961253 (20p12.3), rs355527 (20p12.3), rs4464148 (18q21.1), rs6983267 (8q24.21) and rs10505477 (8q24.21) were significantly associated with survival. The effects were no longer statistically significant, however, after adjustment for multiple testing. Irrespective of correction for multiple testing assuming a prior of 0.001 none of these associations are inherently robust.

10.1371/journal.pone.0117816.t003

###### Findings of other studies investigating the association of CRC susceptibility SNPs with prognosis.
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  Study                                                                          Cohort size   Outcomes assessed   SNPs investigated                                                                                                                                                                                                                                                                                                       
  ------------------------------------------------------------------------------ ------------- ------------------- ------------------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- -- ------- ------- ------- ------- ------- -- ------- ------- -- ------- ------- ------- ------- ------- ------- -- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- -------
  Abuli\[[@pone.0117816.ref017]\]                                                1,235         OS                                      **x**                   **+**                                                                      **x**                              **x**                              **x**           **x**                      **x**                                                                   **x**   **+**
  Cicek\[[@pone.0117816.ref023]\][γ](#t003fn004){ref-type="table-fn"}            460           OS, DFS                                                                                                                    **x**   **x**           **x**                                                                                                    **x**                                                                           
  Dai\[[@pone.0117816.ref018]\][γ](#t003fn004){ref-type="table-fn"}              285           OS, R               \-                  **x**   \-      **x**   **x**   **x**                   **x**   **x**   **x**                      **x**           **x**      **+**   **x**      **x**   \-                              **x**                      \-      **x**           **x**                           **x**   **x**   **+**   **x**
  Garcia-Albeniz\[[@pone.0117816.ref024]\][§](#t003fn003){ref-type="table-fn"}   1,509         OS                                                                                                                                                                                                                               \-                                                                                                         
  Hoskins\[[@pone.0117816.ref019]\]                                              583           OS                  **x**                       **x**           **x**                                                                                                         **x**              **x**   **x**                   **x**                      **x**           **x**   **x**                   **x**                           
  Passarelli\[[@pone.0117816.ref032]\]                                           727           CSS                                                                                                                                                                                              **x**                           **x**                                                                                                      
  Phipps\[[@pone.0117816.ref020]\][§](#t003fn003){ref-type="table-fn"}           2,611         OS, CSS                                 **x**                   **x**           **x**   **x**                                              **x**                              **x**      **x**           **x**           **x**   \-         **x**   **x**   **x**                                   **x**                           **x**   **x**
  Tenesa\[[@pone.0117816.ref021]\]                                               2,838         CSS                                     **x**                   **x**                                                                      **x**                              **x**      **x**           **x**                   **x**                      **x**                                                                   **x**   **x**
  Xing\[[@pone.0117816.ref022]\]                                                 380           OS, DFS                                                         **x**                                           **x**                                                         **x**                      **x**                   **x**                                                      **x**                                           

Key: + significantly increased survival,---significantly decreased survival, X no survival difference observed

OS---Overall survival, DFS---Disease free survival, CSS---cancer specific survival, R---recurrence

§---Based on overlapping cohort of patients

γ- Based on patients with stage II/III cancers.

Only two of the previously reported studies have investigated the influence of rs4444235 on prognosis and they found no significant association with survival \[[@pone.0117816.ref020],[@pone.0117816.ref021]\]. To further examine the association between rs4444235 genotype and OS a meta-analysis pooling our study with these studies was undertaken ([Fig. 3](#pone.0117816.g003){ref-type="fig"}). Collectively, the three studies provided rs4444235 genotypes on a total of 9,686 CRC patients. Using these data, the summary OR was 1.08 (95%CI 1.02--1.14) with the potential of heterogeneity between studies (*P* ~*het*~ = 0.34; I^2^ = 8%).

![Forest plot showing the results of a meta-analysis combining HR for the SNP rs4444235.\
Horizontal lines represent 95% confidence intervals. Each box represents the OR point estimate and its area is proportional to the weight of the study. The diamond (and unbroken line) denotes the overall summary estimate, with CIs given by its width. The unbroken vertical line is at the null value (OR = 1.0).](pone.0117816.g003){#pone.0117816.g003}

DISCUSSION {#sec015}
==========

Here we have provided evidence that variation at 14q22.2 defined by rs4444235 influences CRC outcome independent of established metrics. Although our study did not provide evidence for a relationship between other SNPs our analysis only had 50--70% power to demonstrate a relationship between carrier status for a 10% difference in prognosis, at the 5% threshold. Hence it is not possible to conclusively exclude the possibility that variation at the other CRC risk loci may also be linked to outcome.

Major strengths of our study are its size, the fact that it is drawn from a representative sample of the population, and involved the systematic follow-up of patients. Overall survivorship is unlikely to have influenced study findings, even though case selection in NSCCG is biased to Dukes' stages A and B disease. It therefore seems unlikely that any spurious influences as a consequence of study design will have impacted significantly on our findings. Furthermore, as our analysis was restricted to UK patients with self-reported European ethnicity our study findings are also unlikely to be confounded by population stratification.

We do however acknowledge that a limitation of our study is that we have not addressed potential bias arising from non-uniform treatment. While this is a potential serious confounder in studies of some tumours the management of CRC is relatively uniform within the UK. Support for this assertion is provided by the fact that survival rates observed in our study population were not different to those expected of other unselected patients of a similar stage profile treated in the UK \[[@pone.0117816.ref002]\]. It is likely that the impact of risk variants will be contingent upon interaction with non-genetic risk factors. Unfortunately, such data were not available within the current study to allow such an analysis.

Mechanistically a functional basis for only the 14q22.2 association has yet to be fully elucidated. It is also noteworthy that the risk allele of rs4444235 appears to be preferentially associated with the development of microsatellite stable CRC\[[@pone.0117816.ref029],[@pone.0117816.ref030]\]. This is consistent with the observation that germline mutation in the TGF-β superfamily-signalling pathway genes is associated with microsatellite stable CRC, and hence may impact indirectly on patient outcome. Furthermore, reporter gene studies have demonstrated that the element to which rs4444235 maps acts as an allele-specific transcriptional enhancer. Allele-specific expression studies in CRC cell lines heterozygous for rs4444235 have shown significantly increased expression of bone morphogenetic protein-4 (BMP4) associated with the risk allele providing evidence for a functional basis for the non-coding risk variant \[[@pone.0117816.ref031]\].

This analysis has provided evidence that variation in 14q22.2 plays a role in defining individual patient prognosis. However compelling this association between 14q22.2 and OS is on the basis of biological plausibility as with all association studies independent validation of study findings is required. While previously published studies have not provided support for the 14q22.2 association such studies are small and hence have had limited power to demonstrate a relationship\[[@pone.0117816.ref017]--[@pone.0117816.ref024],[@pone.0117816.ref032]\]. Hence our analysis serves to highlight the statistical problem of searching for genetic associations when the impact of any variant is likely to be at best modest. Even stipulating significance level of 0.05 for an analysis of clinical trial data is unrealistic, because to have 80% power to demonstrate a 5% difference in survival, which is clinically relevant, requires at least 4,800 patient samples to be analysed, even if the frequency of the at risk genotype is 50%. Hence it is therefore not perhaps surprising that previously purported associations cannot be considered robust if FPRP type criteria are imposed.

While germline variants are unlikely to replace staging schemes and conventional markers, they have potential to assist in distinguishing different outcome patterns among patients with the same stage disease where 10% differences are clinically relevant thereby opening up the possibility of a rational, targeted approach to treatment based on a combination of genotype and tumour characteristics of a patient.
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